Novo sues Sanofi
Novo Nordisk (NYSE:NVO) has filed a complaint with a court in New Jersey claiming Sanofi-Aventis (NYSE:SNY) had infringed one of its U.S. insulin pen patents. The case concerns Sanofi’s new disposable insulin pen which is expected to be launched in the United States. Diabetic Investor is not surprised by this move after seeing the pen at the ADA conference in Chicago as it looks and feels very much like Novo’s disposable pens.
This move also reinforces something Diabetic Investor has been saying for years, delivery systems matter and no one has better insulin delivery systems than Novo Nordisk. Lilly (NYSE:LLY) has also introduced several new insulin pens and it wouldn’t surprise Diabetic Investor at all if Novo has already set their sights and will also sue Lilly.
When it comes to IP and the diabetes market, the phrase friendly rivals does not apply.